About Umlaut.bio

Umlaut.bio GmbH develops small molecules that are intended to be used as first-in-class therapeutics against a variety of diseases. The focus is on the “umlauts” of the genetic code – chemically modified RNA nucleotides. These play a crucial role in gene regulation and are of great importance, for example, in cancer cells. There, modified tRNAs protect protein-coding mRNAs from degradation and thus promote tumor growth. Therapeutic modalities that specifically address this mechanism could be able to selectively prevent the growth of cancer cells. This approach promises a disruptive novel form of cancer therapy that could offer a new, gentler treatment option for many patients.